InsidersTradesSigma
Total declarations
Company
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by ALSTODT LANCE, Chairman & CEO. Director active across 1 companies, notably BioRestorative Therapies, Inc.. In total, 22 filings have been published. Total volume traded: €94k. The latest transaction was filed on 30 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations22 total
€3,2531,100 shares@ €2.95690.066% mcap3.5% of flow
Common Stock
SEC:0001567619-22-013553:0·
Ideal exit: 27 Mar 2023 (T+270)
€2,122600 shares@ €3.53660.043% mcap2.3% of flow
Common Stock
SEC:0001567619-22-013067:0·
Ideal exit: 13 Mar 2023 (T+270)
€2,465700 shares@ €3.52150.050% mcap2.6% of flow
Common Stock
SEC:0001567619-22-012910:0·
Ideal exit: 12 Mar 2023 (T+270)
€1,873500 shares@ €3.74680.038% mcap2.0% of flow
Common Stock
SEC:0001567619-22-012867:0·
Ideal exit: 11 Mar 2023 (T+270)
€382100 shares@ €3.82140.0078% mcap0.4% of flow
Common Stock
SEC:0001567619-22-012812:0·
Ideal exit: 10 Mar 2023 (T+270)
€399100 shares@ €3.99340.0082% mcap0.4% of flow
Common Stock
SEC:0001567619-22-012581:0·
Ideal exit: 5 Mar 2023 (T+270)
€864200 shares@ €4.31760.018% mcap0.9% of flow
Common Stock
SEC:0001567619-22-012211:0·
Ideal exit: 26 Feb 2023 (T+270)
€8,8462,700 shares@ €3.27620.18% mcap9.4% of flow
Common Stock
SEC:0001567619-22-011807:0·
Ideal exit: 20 Feb 2023 (T+270)
€749200 shares@ €3.74440.015% mcap0.8% of flow
Common Stock
SEC:0001567619-22-009300:0·
Ideal exit: 27 Jan 2023 (T+270)
12,438 shares
Common Stock
SEC:0001567619-22-007347:0·
€4,4071,470 shares@ €2.99780.090% mcap4.7% of flow
Common Stock
SEC:0001567619-22-001588:0·
Ideal exit: 21 Oct 2022 (T+270)
€4,4071,470 shares@ €2.997812.0% of flow
Common Stock
SEC:0001567619-22-001588·
Ideal exit: 21 Oct 2022 (T+270)
€6,8242,000 shares@ €3.41218.6% of flow
Common Stock
SEC:0001567619-22-000585·
Ideal exit: 2 Oct 2022 (T+270)
€6,8242,000 shares@ €3.4120.14% mcap7.2% of flow
Common Stock
SEC:0001567619-22-000585:0·
Ideal exit: 2 Oct 2022 (T+270)
€3,879799 shares@ €4.854210.6% of flow
Common Stock
SEC:0001567619-21-021415·
Ideal exit: 28 Aug 2022 (T+270)
€3,879799 shares@ €4.85420.079% mcap4.1% of flow
Common Stock
SEC:0001567619-21-021415:0·
Ideal exit: 28 Aug 2022 (T+270)
€13,3432,500 shares@ €5.337136.4% of flow
Common Stock
SEC:0001567619-21-021072·
Ideal exit: 20 Aug 2022 (T+270)
€13,3432,500 shares@ €5.33710.27% mcap14.2% of flow
Common Stock
SEC:0001567619-21-021072:0·
Ideal exit: 20 Aug 2022 (T+270)
€2,216396 shares@ €5.59616.1% of flow
Common Stock
SEC:0001567619-21-020992·
Ideal exit: 19 Aug 2022 (T+270)
€2,216396 shares@ €5.59610.045% mcap2.4% of flow
Common Stock
SEC:0001567619-21-020992:0·
Ideal exit: 19 Aug 2022 (T+270)
€5,9471,000 shares@ €5.947316.2% of flow
Common Stock
SEC:0001567619-21-020595·
Ideal exit: 13 Aug 2022 (T+270)
€5,9471,000 shares@ €5.94730.12% mcap6.3% of flow
Common Stock
SEC:0001567619-21-020595:0·
Ideal exit: 13 Aug 2022 (T+270)
22 of 22 declarations
About ALSTODT LANCE
Lance Alstodt is an executive at BioRestorative Therapies, Inc.
